UK Covid-19 Public Inquiry – chapter 1

Module 4, report from day 1 of the hearings to which we are not invited. HART was one of a number of groups who were asked to provide detailed witness statements to the Inquiry, only to find we will not be called to give oral evidence. The Inquiry legal team have apparently shared our statements with the Core Participants and indeed with one of their commissioned experts, but have not as yet confirmed whether or not our statements will be available on the Inquiry website.
Preliminary statements from day 1 are not encouraging!

Read More

Divide and Conquer

Our drug safety monitoring systems are designed to identify an increase in the incidence of a rare condition. That is why they worked relatively well at identifying the Cerebral Venous Sinus Thrombosis and myocarditis cases. They are bad at identifying increases in more common conditions and terrible at identifying multi-system conditions.

Read More